Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity.
Researchers at Flinders University, Adelaide, Australia, have demonstrated a potential molecular link between COVID-19 and serotonin cells in the gut, suggesting that gut health may have a role to play in driving COVID-19 infection.
The collaborative study investigated gene expression amongst various different cell types lining the gut wall, sequencing and analysing whole genomes from thousands of individuals cells within the intestine. Specialised cells in the gut that synthesised and released serotonin were also discovered to possess a highly enriched expression of a specific SARS-CoV-2 receptor, and were the only type of cells to express all genes associated with COVID-19.
The research may provide further insight into what drives COVID-19 infection and disease severity, potentially supporting previous evidence suggesting antidepressants known as selective serotonin reuptake inhibitors could reduce the severity of COVID-19 symptoms after infection.
Damien Keating, professor and Deputy Director of the Flinders Health and Medical Research Institute and Head of the Gut Sensory Systems research group, commented: “Our study endeavoured to understand whether the gut could be a site of disease transmission and what genes might be associated with the virus entering the cells lining the gut wall.” As the exact site of infection and primary drivers of COVID-19 severity are yet to be fully understood, the researchers behind this study hope to provide important information on the gut’s role in the virus. “Our study adds further evidence that COVID-19 is far more likely to infect cells in the gut and increase serotonin levels through direct effects on the specific gut cells, potentially worsening disease outcomes,” added Keating. “As COVID-19 continues to circulate, further research will be required to advance our understanding of the gut’s role in the virus and continue to find treatment options to work alongside vaccinations.”
The study was published in leading gastrointestinal research journal Gut.
Want to know more about the gut and how it affects overall health? Read our Consumer health trends webinar roundup on the gut microbiome, or watch the webinar itself on-demand.
Source: How the gut may help to drive COVID-19 – News (flinders.edu.au)
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance